Assessing osteopenia and osteoporosis with dual-energy x-ray absorptiometry studies in Fabry disease
Background Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treat...
Saved in:
Published in | Orphanet journal of rare diseases Vol. 20; no. 1; pp. 206 - 9 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
30.04.2025
BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1750-1172 1750-1172 |
DOI | 10.1186/s13023-025-03601-x |
Cover
Abstract | Background
Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD.
Materials and methods
To ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California—Irvine Medical Center for the period 2008–2023. The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within ± 9 months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51 years (median 56 years, range 18–77 years). The Z-scores for all participants and T-scores from postmenopausal women and men ≥ 50-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results.
Results
The average Z-score for all the participants was −1.2 ± 1.3 (range −4.6 to 1.6). Twenty-four percent of all participants (
n =
6) had significantly low Z-scores ≤ −2.0. To identify the frequency of subjects with osteopenia, defined as T-score between −1.0 and −2.5 and osteoporosis defined as T-score < −2.5, T-scores were analyzed in postmenopausal women (
n =
8) and men 50 years and older (
n =
7). Of these 15 individuals, average T-score was −2.2 ± 1.3 (range −5.4 to 0.3), and 86.7% (
n =
13) had abnormal results (osteopenia and osteoporosis), 53.3% (
n =
8) had osteoporosis and 33.3% (
n =
5) had osteoporosis. We found a significant difference in Z-scores between male (−1.98 ± 1.33) and female patients (−.45 ± 0.82) t (23) = 3.487 (
p =
< 0.001). We did not find any differences in z-scores between different ethnic backgrounds. There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15) = −.72,
p =
.001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23) = .43,
p =
.033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8) = -.86,
p =
.001] and a negative correlation between T-scores and participants’ ages at the time of DXA [r (13) = −.57,
p =
0.028]. There is a positive correlation between T- scores and calcium levels [r (12) = .58,
p =
0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications.
Conclusion
The findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia/osteoporosis in Fabry disease. |
---|---|
AbstractList | Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD. To ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California--Irvine Medical Center for the period 2008-2023. The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within ± 9 months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51 years (median 56 years, range 18-77 years). The Z-scores for all participants and T-scores from postmenopausal women and men [greater than or equal to] 50-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results. The average Z-score for all the participants was -1.2 ± 1.3 (range -4.6 to 1.6). Twenty-four percent of all participants (n = 6) had significantly low Z-scores [less than or equal to] -2.0. To identify the frequency of subjects with osteopenia, defined as T-score between -1.0 and -2.5 and osteoporosis defined as T-score < -2.5, T-scores were analyzed in postmenopausal women (n = 8) and men 50 years and older (n = 7). Of these 15 individuals, average T-score was -2.2 ± 1.3 (range -5.4 to 0.3), and 86.7% (n = 13) had abnormal results (osteopenia and osteoporosis), 53.3% (n = 8) had osteoporosis and 33.3% (n = 5) had osteoporosis. We found a significant difference in Z-scores between male (-1.98 ± 1.33) and female patients (-.45 ± 0.82) t (23) = 3.487 (p = < 0.001). We did not find any differences in z-scores between different ethnic backgrounds. There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15) = -.72, p = .001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23) = .43, p = .033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8) = -.86, p = .001] and a negative correlation between T-scores and participants' ages at the time of DXA [r (13) = -.57, p = 0.028]. There is a positive correlation between T- scores and calcium levels [r (12) = .58, p = 0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications. The findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia/osteoporosis in Fabry disease. Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD.BACKGROUNDFabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD.To ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California-Irvine Medical Center for the period 2008-2023. The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within ± 9 months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51 years (median 56 years, range 18-77 years). The Z-scores for all participants and T-scores from postmenopausal women and men ≥ 50-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results.MATERIALS AND METHODSTo ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California-Irvine Medical Center for the period 2008-2023. The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within ± 9 months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51 years (median 56 years, range 18-77 years). The Z-scores for all participants and T-scores from postmenopausal women and men ≥ 50-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results.The average Z-score for all the participants was -1.2 ± 1.3 (range -4.6 to 1.6). Twenty-four percent of all participants (n = 6) had significantly low Z-scores ≤ -2.0. To identify the frequency of subjects with osteopenia, defined as T-score between -1.0 and -2.5 and osteoporosis defined as T-score < -2.5, T-scores were analyzed in postmenopausal women (n = 8) and men 50 years and older (n = 7). Of these 15 individuals, average T-score was -2.2 ± 1.3 (range -5.4 to 0.3), and 86.7% (n = 13) had abnormal results (osteopenia and osteoporosis), 53.3% (n = 8) had osteoporosis and 33.3% (n = 5) had osteoporosis. We found a significant difference in Z-scores between male (-1.98 ± 1.33) and female patients (-.45 ± 0.82) t (23) = 3.487 (p = < 0.001). We did not find any differences in z-scores between different ethnic backgrounds. There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15) = -.72, p = .001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23) = .43, p = .033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8) = -.86, p = .001] and a negative correlation between T-scores and participants' ages at the time of DXA [r (13) = -.57, p = 0.028]. There is a positive correlation between T- scores and calcium levels [r (12) = .58, p = 0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications.RESULTSThe average Z-score for all the participants was -1.2 ± 1.3 (range -4.6 to 1.6). Twenty-four percent of all participants (n = 6) had significantly low Z-scores ≤ -2.0. To identify the frequency of subjects with osteopenia, defined as T-score between -1.0 and -2.5 and osteoporosis defined as T-score < -2.5, T-scores were analyzed in postmenopausal women (n = 8) and men 50 years and older (n = 7). Of these 15 individuals, average T-score was -2.2 ± 1.3 (range -5.4 to 0.3), and 86.7% (n = 13) had abnormal results (osteopenia and osteoporosis), 53.3% (n = 8) had osteoporosis and 33.3% (n = 5) had osteoporosis. We found a significant difference in Z-scores between male (-1.98 ± 1.33) and female patients (-.45 ± 0.82) t (23) = 3.487 (p = < 0.001). We did not find any differences in z-scores between different ethnic backgrounds. There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15) = -.72, p = .001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23) = .43, p = .033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8) = -.86, p = .001] and a negative correlation between T-scores and participants' ages at the time of DXA [r (13) = -.57, p = 0.028]. There is a positive correlation between T- scores and calcium levels [r (12) = .58, p = 0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications.The findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia/osteoporosis in Fabry disease.CONCLUSIONThe findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia/osteoporosis in Fabry disease. Background Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD. Materials and methods To ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California—Irvine Medical Center for the period 2008–2023. The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within ± 9 months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51 years (median 56 years, range 18–77 years). The Z-scores for all participants and T-scores from postmenopausal women and men ≥ 50-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results. Results The average Z-score for all the participants was −1.2 ± 1.3 (range −4.6 to 1.6). Twenty-four percent of all participants ( n = 6) had significantly low Z-scores ≤ −2.0. To identify the frequency of subjects with osteopenia, defined as T-score between −1.0 and −2.5 and osteoporosis defined as T-score < −2.5, T-scores were analyzed in postmenopausal women ( n = 8) and men 50 years and older ( n = 7). Of these 15 individuals, average T-score was −2.2 ± 1.3 (range −5.4 to 0.3), and 86.7% ( n = 13) had abnormal results (osteopenia and osteoporosis), 53.3% ( n = 8) had osteoporosis and 33.3% ( n = 5) had osteoporosis. We found a significant difference in Z-scores between male (−1.98 ± 1.33) and female patients (−.45 ± 0.82) t (23) = 3.487 ( p = < 0.001). We did not find any differences in z-scores between different ethnic backgrounds. There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15) = −.72, p = .001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23) = .43, p = .033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8) = -.86, p = .001] and a negative correlation between T-scores and participants’ ages at the time of DXA [r (13) = −.57, p = 0.028]. There is a positive correlation between T- scores and calcium levels [r (12) = .58, p = 0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications. Conclusion The findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia/osteoporosis in Fabry disease. Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD. To ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California-Irvine Medical Center for the period 2008-2023. The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within ± 9 months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51 years (median 56 years, range 18-77 years). The Z-scores for all participants and T-scores from postmenopausal women and men ≥ 50-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results. The average Z-score for all the participants was -1.2 ± 1.3 (range -4.6 to 1.6). Twenty-four percent of all participants (n = 6) had significantly low Z-scores ≤ -2.0. To identify the frequency of subjects with osteopenia, defined as T-score between -1.0 and -2.5 and osteoporosis defined as T-score < -2.5, T-scores were analyzed in postmenopausal women (n = 8) and men 50 years and older (n = 7). Of these 15 individuals, average T-score was -2.2 ± 1.3 (range -5.4 to 0.3), and 86.7% (n = 13) had abnormal results (osteopenia and osteoporosis), 53.3% (n = 8) had osteoporosis and 33.3% (n = 5) had osteoporosis. We found a significant difference in Z-scores between male (-1.98 ± 1.33) and female patients (-.45 ± 0.82) t (23) = 3.487 (p = < 0.001). We did not find any differences in z-scores between different ethnic backgrounds. There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15) = -.72, p = .001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23) = .43, p = .033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8) = -.86, p = .001] and a negative correlation between T-scores and participants' ages at the time of DXA [r (13) = -.57, p = 0.028]. There is a positive correlation between T- scores and calcium levels [r (12) = .58, p = 0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications. The findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia/osteoporosis in Fabry disease. Background Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD. Materials and methods To ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California--Irvine Medical Center for the period 2008-2023. The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within ± 9 months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51 years (median 56 years, range 18-77 years). The Z-scores for all participants and T-scores from postmenopausal women and men [greater than or equal to] 50-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results. Results The average Z-score for all the participants was -1.2 ± 1.3 (range -4.6 to 1.6). Twenty-four percent of all participants (n = 6) had significantly low Z-scores [less than or equal to] -2.0. To identify the frequency of subjects with osteopenia, defined as T-score between -1.0 and -2.5 and osteoporosis defined as T-score < -2.5, T-scores were analyzed in postmenopausal women (n = 8) and men 50 years and older (n = 7). Of these 15 individuals, average T-score was -2.2 ± 1.3 (range -5.4 to 0.3), and 86.7% (n = 13) had abnormal results (osteopenia and osteoporosis), 53.3% (n = 8) had osteoporosis and 33.3% (n = 5) had osteoporosis. We found a significant difference in Z-scores between male (-1.98 ± 1.33) and female patients (-.45 ± 0.82) t (23) = 3.487 (p = < 0.001). We did not find any differences in z-scores between different ethnic backgrounds. There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15) = -.72, p = .001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23) = .43, p = .033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8) = -.86, p = .001] and a negative correlation between T-scores and participants' ages at the time of DXA [r (13) = -.57, p = 0.028]. There is a positive correlation between T- scores and calcium levels [r (12) = .58, p = 0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications. Conclusion The findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia/osteoporosis in Fabry disease. Keywords: Fabry disease, DXA, Bone mineral density, Enzyme replacement therapy Abstract Background Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD. Materials and methods To ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California—Irvine Medical Center for the period 2008–2023. The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within ± 9 months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51 years (median 56 years, range 18–77 years). The Z-scores for all participants and T-scores from postmenopausal women and men ≥ 50-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results. Results The average Z-score for all the participants was −1.2 ± 1.3 (range −4.6 to 1.6). Twenty-four percent of all participants (n = 6) had significantly low Z-scores ≤ −2.0. To identify the frequency of subjects with osteopenia, defined as T-score between −1.0 and −2.5 and osteoporosis defined as T-score < −2.5, T-scores were analyzed in postmenopausal women (n = 8) and men 50 years and older (n = 7). Of these 15 individuals, average T-score was −2.2 ± 1.3 (range −5.4 to 0.3), and 86.7% (n = 13) had abnormal results (osteopenia and osteoporosis), 53.3% (n = 8) had osteoporosis and 33.3% (n = 5) had osteoporosis. We found a significant difference in Z-scores between male (−1.98 ± 1.33) and female patients (−.45 ± 0.82) t (23) = 3.487 (p = < 0.001). We did not find any differences in z-scores between different ethnic backgrounds. There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15) = −.72, p = .001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23) = .43, p = .033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8) = -.86, p = .001] and a negative correlation between T-scores and participants’ ages at the time of DXA [r (13) = −.57, p = 0.028]. There is a positive correlation between T- scores and calcium levels [r (12) = .58, p = 0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications. Conclusion The findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia/osteoporosis in Fabry disease. |
ArticleNumber | 206 |
Audience | Academic |
Author | Sadri, Nadia Martin-Rios, Angela Lee, Grace Valentine, Kelsey Shmara, Alyaa Kimonis, Virginia Pahl, Madeleine Mgdsyan, Mania Hall, Kathy Polgreen, Lynda E. Kain, Tatiana |
Author_xml | – sequence: 1 givenname: Alyaa surname: Shmara fullname: Shmara, Alyaa organization: Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California Irvine – sequence: 2 givenname: Grace surname: Lee fullname: Lee, Grace organization: Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California Irvine – sequence: 3 givenname: Mania surname: Mgdsyan fullname: Mgdsyan, Mania organization: Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California Irvine, College of Osteopathic Medicine, Western University of Health Sciences – sequence: 4 givenname: Kathy surname: Hall fullname: Hall, Kathy organization: Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California Irvine – sequence: 5 givenname: Nadia surname: Sadri fullname: Sadri, Nadia organization: Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California Irvine, College of Arts and Sciences, New York University – sequence: 6 givenname: Angela surname: Martin-Rios fullname: Martin-Rios, Angela organization: Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California Irvine – sequence: 7 givenname: Kelsey surname: Valentine fullname: Valentine, Kelsey organization: Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California Irvine – sequence: 8 givenname: Tatiana surname: Kain fullname: Kain, Tatiana organization: Nuclear Medicine, Department of Radiology, University of California – sequence: 9 givenname: Madeleine surname: Pahl fullname: Pahl, Madeleine organization: Division of Nephrology, Department of Medicine, Hypertension, and Kidney Transplantation, University of California – sequence: 10 givenname: Lynda E. surname: Polgreen fullname: Polgreen, Lynda E. organization: The Lundquist Institute for Biomedical Innovation at Harbor, UCLA Medical Center – sequence: 11 givenname: Virginia orcidid: 0000-0003-1567-4449 surname: Kimonis fullname: Kimonis, Virginia email: vkimonis@hs.uci.edu organization: Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California Irvine, Department of Neurology, University of California, Department of Pathology, University of California |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40301993$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktr3DAURk1JaR7tH-iiGLppF071sCV7VYbQtAOBQh9rIUtXjsKMNNW105l_X008DRkoxQtZV-f7kOCcFychBiiK15RcUtqKD0g5YbwirKkIF4RW22fFGZUNqSiV7OTJ_2lxjnhHSN1w0r4oTmvCCe06flbYBSIg-jCUEUeIGwhelzrYwzamiB7L3368Le2kVxUESMOu3FZJ70rdY0yb0cc1jGlX4jhZD1j6UF7rPg-sR9AIL4vnTq8QXh3Wi-Ln9acfV1-qm6-fl1eLm8o0Qo4VSKpr6VzjagOEMeOYaXvLOLSdoQ3re8ca0vSu77reCqGlsJ3Rtu6dZEYLflEs514b9Z3aJL_Waaei9uphENOgdBq9WYEShvS2MZQI09Zt03aWCaMdaaWuay157vo4d22mfg3WQBiTXh2VHp8Ef6uGeK8oIzXjrM0N7w4NKf6aAEe19mhgtdIB4oSK006Kmku5R9_O6KDz3XxwMVeaPa4WLZdCdpTsr3T5Dyp_FtbeZDecz_OjwPujQGZG2I6DnhDV8vu3Y_bN0_c-PvSvKhlgM2CyEpjAPSKUqL2PavZRZR_Vg49qm0N8DmGGwwBJ3cUphSzB_1J_AHbx48s |
Cites_doi | 10.1097/gim.0b013e31815cb197 10.1016/j.bone.2015.12.057 10.1007/8904_2014_328 10.1007/s00467-023-06050-5 10.1016/j.bone.2008.08.106 10.1002/iub.257 10.1016/j.ymgme.2023.107634 10.1056/NEJMoa2102953 10.1007/s11914-996-0016-3 10.1115/1.2895412 10.1007/s00198-022-06420-z 10.1007/s40519-018-0505-2 10.1016/j.ymgmr.2020.100700 10.3390/biom11070951 10.1136/bmj.312.7041.1254 10.1155/2001/768501 10.1111/j.1399-0004.2005.00457.x 10.1016/j.ymgme.2019.10.010 10.1002/jbmr.2058 10.1016/j.ymgme.2010.03.020 10.1016/s0969-8043(98)00026-8 10.1007/BF00296209 10.1096/fba.2019-00080 10.1007/s10067-015-2883-4 10.1016/j.bone.2020.115581 10.1079/BJNBJN/2002534 10.1016/j.ymgme.2022.10.005 |
ContentType | Journal Article |
Copyright | The Author(s) 2025 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 7X8 5PM DOA |
DOI | 10.1186/s13023-025-03601-x |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1750-1172 |
EndPage | 9 |
ExternalDocumentID | oai_doaj_org_article_6c0bd5c106c848589d26caf087a44a73 PMC12042328 A837679103 40301993 10_1186_s13023_025_03601_x |
Genre | Journal Article |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GrantInformation_xml | – fundername: Sanofi funderid: http://dx.doi.org/10.13039/100004339 |
GroupedDBID | --- 0R~ 123 29N 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ISR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 7X8 5PM |
ID | FETCH-LOGICAL-c567t-e71a47ff5f4ce022cf2c8bd23e89c152bbf2505bfb99bd66a76d9cad4bf72ca63 |
IEDL.DBID | M48 |
ISSN | 1750-1172 |
IngestDate | Wed Aug 27 01:31:23 EDT 2025 Thu Aug 21 18:26:33 EDT 2025 Fri Sep 05 17:37:44 EDT 2025 Tue Jun 17 21:56:57 EDT 2025 Tue Jun 10 20:58:09 EDT 2025 Fri Jun 27 05:13:15 EDT 2025 Mon Jul 21 06:08:17 EDT 2025 Tue Aug 05 11:57:54 EDT 2025 Sat Sep 06 07:28:59 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Fabry disease Bone mineral density DXA Enzyme replacement therapy |
Language | English |
License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c567t-e71a47ff5f4ce022cf2c8bd23e89c152bbf2505bfb99bd66a76d9cad4bf72ca63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-1567-4449 |
OpenAccessLink | https://doaj.org/article/6c0bd5c106c848589d26caf087a44a73 |
PMID | 40301993 |
PQID | 3197643778 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6c0bd5c106c848589d26caf087a44a73 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12042328 proquest_miscellaneous_3197643778 gale_infotracmisc_A837679103 gale_infotracacademiconefile_A837679103 gale_incontextgauss_ISR_A837679103 pubmed_primary_40301993 crossref_primary_10_1186_s13023_025_03601_x springer_journals_10_1186_s13023_025_03601_x |
PublicationCentury | 2000 |
PublicationDate | 2025-04-30 |
PublicationDateYYYYMMDD | 2025-04-30 |
PublicationDate_xml | – month: 04 year: 2025 text: 2025-04-30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Orphanet journal of rare diseases |
PublicationTitleAbbrev | Orphanet J Rare Dis |
PublicationTitleAlternate | Orphanet J Rare Dis |
PublicationYear | 2025 |
Publisher | BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
References | JC Lotz (3601_CR12) 1991; 113 J Avarappattu (3601_CR24) 2024; 39 V Gragnaniello (3601_CR2) 2021; 11 Y Nose (3601_CR8) 2023; 139 BS Zemel (3601_CR29) 2020; 141 S Bruell (3601_CR18) 2022; 33 3601_CR15 H Maruyama (3601_CR19) 2020; 2 EM Lewiecki (3601_CR9) 2005; 3 D Marshall (3601_CR13) 1996; 312 A Fassio (3601_CR20) 2018; 23 EM Lewiecki (3601_CR14) 2008; 43 KD Cashman (3601_CR17) 2002; 87 PA Rozenfeld (3601_CR16) 2009; 61 A Kjellgren (3601_CR25) 2001; 6 DP Germain (3601_CR4) 2005; 68 C Tøndel (3601_CR23) 2022; 137 PA Rozenfeld (3601_CR21) 2020; 129 3601_CR27 CF Njeh (3601_CR11) 1999; 50 D Grimm (3601_CR26) 2016; 87 3601_CR1 3601_CR5 M Dutra-Clarke (3601_CR3) 2021; 26 R Mazess (3601_CR10) 1992; 51 LG Schipper (3601_CR22) 2015; 34 PD Miller (3601_CR28) 2013; 28 T Togawa (3601_CR6) 2010; 100 3601_CR7 |
References_xml | – ident: 3601_CR5 doi: 10.1097/gim.0b013e31815cb197 – volume: 87 start-page: 44 year: 2016 ident: 3601_CR26 publication-title: Bone doi: 10.1016/j.bone.2015.12.057 – ident: 3601_CR7 doi: 10.1007/8904_2014_328 – volume: 39 start-page: 131 issue: 1 year: 2024 ident: 3601_CR24 publication-title: Pediatric nephrology (Berlin, Germany) doi: 10.1007/s00467-023-06050-5 – volume: 43 start-page: 1115 issue: 6 year: 2008 ident: 3601_CR14 publication-title: Bone doi: 10.1016/j.bone.2008.08.106 – volume: 61 start-page: 1043 issue: 11 year: 2009 ident: 3601_CR16 publication-title: IUBMB Life doi: 10.1002/iub.257 – volume: 139 issue: 4 year: 2023 ident: 3601_CR8 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2023.107634 – ident: 3601_CR15 doi: 10.1056/NEJMoa2102953 – volume: 3 start-page: 136 issue: 4 year: 2005 ident: 3601_CR9 publication-title: Curr Osteoporos Rep doi: 10.1007/s11914-996-0016-3 – volume: 113 start-page: 353 issue: 4 year: 1991 ident: 3601_CR12 publication-title: J Biomech Eng doi: 10.1115/1.2895412 – volume: 33 start-page: 1783 year: 2022 ident: 3601_CR18 publication-title: Osteoporos Int doi: 10.1007/s00198-022-06420-z – volume: 23 start-page: 293 issue: 3 year: 2018 ident: 3601_CR20 publication-title: Eating and weight disorders: EWD doi: 10.1007/s40519-018-0505-2 – volume: 26 year: 2021 ident: 3601_CR3 publication-title: Molecular Genetics and Metabolism Reports doi: 10.1016/j.ymgmr.2020.100700 – volume: 11 start-page: 951 issue: 7 year: 2021 ident: 3601_CR2 publication-title: Biomolecules doi: 10.3390/biom11070951 – volume: 312 start-page: 1254 issue: 7041 year: 1996 ident: 3601_CR13 publication-title: BMJ (Clinical research ed) doi: 10.1136/bmj.312.7041.1254 – volume: 6 start-page: 181 issue: 4 year: 2001 ident: 3601_CR25 publication-title: Pain Res Manage doi: 10.1155/2001/768501 – ident: 3601_CR1 – volume: 68 start-page: 93 issue: 1 year: 2005 ident: 3601_CR4 publication-title: Clin Genet doi: 10.1111/j.1399-0004.2005.00457.x – volume: 129 start-page: 132 issue: 2 year: 2020 ident: 3601_CR21 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2019.10.010 – volume: 28 start-page: 2049 issue: 10 year: 2013 ident: 3601_CR28 publication-title: Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research doi: 10.1002/jbmr.2058 – volume: 100 start-page: 257 issue: 3 year: 2010 ident: 3601_CR6 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2010.03.020 – volume: 50 start-page: 215 issue: 1 year: 1999 ident: 3601_CR11 publication-title: Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine doi: 10.1016/s0969-8043(98)00026-8 – volume: 51 start-page: 14 issue: 1 year: 1992 ident: 3601_CR10 publication-title: Calcif Tissue Int doi: 10.1007/BF00296209 – volume: 2 start-page: 365 issue: 6 year: 2020 ident: 3601_CR19 publication-title: FASEB bioAdvances doi: 10.1096/fba.2019-00080 – volume: 34 start-page: 1341 issue: 8 year: 2015 ident: 3601_CR22 publication-title: Clin Rheumatol doi: 10.1007/s10067-015-2883-4 – volume: 141 year: 2020 ident: 3601_CR29 publication-title: Bone doi: 10.1016/j.bone.2020.115581 – volume: 87 start-page: S169 issue: Suppl 2 year: 2002 ident: 3601_CR17 publication-title: Br J Nutr doi: 10.1079/BJNBJN/2002534 – ident: 3601_CR27 – volume: 137 start-page: 328 issue: 4 year: 2022 ident: 3601_CR23 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2022.10.005 |
SSID | ssj0045308 |
Score | 2.4283147 |
Snippet | Background
Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated... Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation... Background Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated... Abstract Background Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 206 |
SubjectTerms | Absorptiometry, Photon - methods Adult Aged Alfacalcidol Analysis Bone Density - physiology Bone Diseases, Metabolic - diagnostic imaging Bone mineral density Calcifediol Complications and side effects Denosumab Development and progression Diseases DXA Enzyme replacement therapy Fabry disease Fabry Disease - diagnostic imaging Fabry's disease Female Femur Neck Human Genetics Humans Male Medical research Medicine Medicine & Public Health Medicine, Experimental Middle Aged Osteopenia Osteoporosis Osteoporosis - diagnostic imaging Pharmacology/Toxicology Phosphatases Physiological aspects Postmenopausal women Risk factors Vitamin D X-rays Zoledronic acid |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gIIOQOEDUTdavHAtiVZDKAajUmzV-wR5I0GZX2v57ZpykaooEF46JJ1HsGc8jM_OZsVdBOELpimUTNf2tCr4El5pS-SaaygMoSc3Jp5_VyZn4dC7Prxz1RTVhAzzwsHBHyi9ckB4jF2-EkaYJtfKQFkaDEKAzzieasSmYGnSwkMuFmVpkjDrqKT1H-UpZosbGAHo_M0MZrf9PnXzFKF0vmLyWNc3GaHWH3R69SH48fP1ddiO299jN0zFPfp-FIZeLz3Jq4qAjstbAoQ3jZYcfte45_YTl1IxVxtwCyPflBi44uL7bkCr5GbebC94PpYZ83fIVOLwxJnUesLPVh2_vT8rxPIXSS6W3ZdQVCJ2STMJHtN0-1d64UC-jaTzacecSOUQuuaZxQSnQKjQekJ1J1x7U8iE7aLs2PmbcLYKvKm8kgBPLYBx6jqBiUEk7CJUv2Jtpee2vATbD5nDDKDswwyIzbGaG3RfsHXHgkpIgr_MNFAQ7CoL9lyAU7CXxzxKoRUtVM99h1_f249cv9tgQZg06Rkj0eiRKHXLSw9iEgLMiHKwZ5eGMEnednw2_mMTE0hCVqrWx2_UWdZqmbKg2BXs0iM3lxAQFoOgRFszMBGo28_lIu_6RQb-rmiqYanzp20n27Khu-r8s7ZP_sbRP2a067x1Koh2yg-1mF5-hL7Z1z_O2-w3uWDMG priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQkRAXxJvQggxC4gARm8SvHMuKVUEqB6BSb9b4RfdAgja7UvvvO5NH1RSExDH2JIrz2TNjz8wXxt4E4YilK-Z11HRaFXwOLtW58nU0hQdQkoqTj7-qoxPx5VSejjQ5VAtzPX5fGPWho8AaRRpljroWt77oL96W2Ejpe0u1nLSukNXCTEUxf71vZnh6fv4_tfA1M3QzRfJGnLQ3P6v77N7oN_LDAegH7FZsHrI7x2Nk_BELQ_QW7-VUtkE_xVoDhyaMly2-1LrjdOzKqfwqj33RHz_PN3DBwXXthpTHr7jdXPBuSC7k64avwGHDGMZ5zE5Wn34sj_LxDwq5l0pv86gLEDolmYSPaK19Kr1xoayiqT1abucSuUAuubp2QSnQKtQeEMCkSw-qesL2mraJzxh3i-CLwhsJ4EQVjENfEVQMKmkHofAZezd9Xvt7IMqw_QbDKDuAYREM24NhzzP2kRC4kiSS674BsbfjmrHKL1yQHjet3ggjTR1K5SEtjAYhQFcZe034WaKxaChP5ifsus5-_v7NHhpiqUFXCIXejkKpRSQ9jGUHOCpivppJHswkcZ35WferaZpY6qLktCa2u86iFtMU_9QmY0-HaXM1MEFbTvQBM2ZmE2o28nlPsz7rab6LknKWSnzo-2nu2VHBdP_4tM__T3yf3S37VUIBsgO2t93s4gv0s7buZb_ALgEn5yQJ priority: 102 providerName: Springer Nature |
Title | Assessing osteopenia and osteoporosis with dual-energy x-ray absorptiometry studies in Fabry disease |
URI | https://link.springer.com/article/10.1186/s13023-025-03601-x https://www.ncbi.nlm.nih.gov/pubmed/40301993 https://www.proquest.com/docview/3197643778 https://pubmed.ncbi.nlm.nih.gov/PMC12042328 https://doaj.org/article/6c0bd5c106c848589d26caf087a44a73 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: KQ8 dateStart: 20060101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: ABDBF dateStart: 20060101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: DIK dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: GX1 dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RPM dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1750-1172 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: M48 dateStart: 20060401 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: Springer Nature HAS Fully OA customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: AAJSJ dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: C6C dateStart: 20061201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1db9Mw0BqbNO0F8U1hVAYh8QCBJnFs5wGhrlo1KnVCG5X2ZvkroxIkkLRS---5y0dFxuApin2JbN-d7873YUJeO2awSpcPUi_wtMrZQJssDbhNvQyt1jzB5OT5OT9bsNlVcrVHuuuO2gWsbjXt8D6pRfn9_ebX9hMw_Mea4SX_UKHzDb2RSQD7MZjHoFMegGSKkMrnbOdVYEk8kl3izK3fHZFDhjZCmsY9OVWX8_970_5Dat2MqLzhVq2l1fQeuduqmXTc0MV9sufzB-Rw3jrSHxLXOHvhW4pZHjjnpaY6d-1rAYNaVhRPaSlmawW-zhGkm6DUW6pNVZS41_zwq3JLqyYWkS5zOtUGGlqvzyOymJ5-nZwF7YULgU24WAVehJqJLEsyZj0Id5tFVhoXxV6mFgS9MRlqTCYzaWoc51pwl1oN-M5EZDWPH5P9vMj9U0LNyNkwtDLR2rDYSQOqpebe8UwY7UI7IG-75VU_m7oaqrZHJFcNXhTgRdV4UZsBOUEM7CCxJnbdUJTXqmUxxe3IuMSCjWslk4lMXcStzkZSaMa0iAfkFeJPYdWLHMNqrvW6qtTnyws1lljUBjQnAHrTAmUFYNLqNksBZoWFsnqQxz1IYEvb637ZkYnCLoxly32xrhRsegLdpUIOyJOGbHYT66hvQGSPoHoz7_fky291VfAwwhCnCH76rqM91bHTf5b22T_H8JwcRTVvoOvsmOyvyrV_ARrYygzJHXElhuRgPJ5dzuB5cnr-5QJaJ3wyrE81hjXj_QYtwDPY |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELbQVgIuiDcLBQxC4gBRN1m_clwQq-3S7YG2Um_W-FX2QII2u1L77_EkTkUKQuKYeBzFHs_D_mbGhLxzzGCVLp-VXuJplbMZmFBmwpZe5RZAcExOXh2LxRlbnvPzlBTW9NHuPSTZaupWrJU4aBBiQ8yRZ1Hrxk1w9Bz3FOeCjcjebLY8WfYamPHpRPUJMn_tOTBCba3-PzXybybpZrjkDcy0NUXz--Re8iHprGP6A3LLVw_J7VVCyR8R1yG5sS_FFA68IGsNFCqXHuv4U-uG4hEsxVSszLcJgPQy28AVBdPUG1QkP_x2c0WbLtCQris6BxNfJEjnMTmbfzn9vMjSbQqZ5UJuMy9zYDIEHpj10XLbUFhlXDH1qrTRihsT0B0ywZSlcUKAFK60EJkZZGFBTJ-QUVVX_hmhZuJsnlvFAQybOmWi3wjCOxGkAZfbMfnQT6_-2RXN0O1mQwndMUNHZuiWGfpyTD4hB64pseB1-6LeXOgkP1rYiXHcxg2sVUxxVbpCWAgTJYExkNMxeYv801jSosKYmQvYNY0-PPmmZwor1kS3KBK9T0Shjpy0kFIQ4qiwCtaAcn9AGWXODprf9MtEYxMGqlW-3jU6ajSJWKhUY_K0WzbXA2O4_Yz-4JiowYIajHzYUq2_tyW_8wLjl4r40Y_92tNJ2TT_mNrn_0f-mtxZnK6O9NHh8dcX5G7RSgwCZ_tktN3s_Mvof23NqyRuvwBtpyxq |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9VAEF6kheKLeDdadRXBBw09ue1uHo-XQ3u0RayFvi2zt3oeTMpJDrT_3plcSlNF8DHZSchm7vlmJoy9cbmhKV0-Lr2kr1XOxmBCGQtbepVYAFFQc_Lhkdg_yZenxem1Lv6u2n2EJPueBprSVLV75y70Kq7EXkNwG-GPRYwWGBNijCK3VVEKTL-25_Pl8XK0xnmRzdTYLPPXKycOqZvb_6d1vuaebpZO3sBPO7e0uMvuDPEkn_cCcI_d8tV9tnM4IOYPmOtRXbyWUzsH_SxrBRwqNxzW-FCrhtPnWE5tWbHvmgH5RbyGSw6mqddkVH75dn3Jm77okK8qvgCDJwZ45yE7WXz-8XE_Hv6sENtCyDb2MoFchlCE3Hr04jakVhmXZl6VFj26MYFCIxNMWRonBEjhSgvI2CBTCyJ7xLaquvJPGDczZ5PEqgLA5JlTBmNIEN6JIA24xEbs3fh69Xk_QEN3iYcSumeGRmbojhn6ImIfiANXlDT8ujtRr8_0oEta2JlxhcVk1qpcFap0qbAQZkpCnoPMIvaa-KdpvEVF9TNnsGkafXD8Xc8VTa_BEAmJ3g5EoUZOWhjaEXBXNBFrQrk7oUT9s5PlV6OYaFqiorXK15tGo3WThItKFbHHvdhcbSynVBRjw4ipiUBNdj5dqVY_u_HfSUq1TCne9P0oe3owPM0_Xu3T_yN_yXa-fVrorwdHX56x22mnMISh7bKtdr3xzzEUa82LQdt-AyWdMLQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessing+osteopenia+and+osteoporosis+with+dual-energy+x-ray+absorptiometry+studies+in+Fabry+disease&rft.jtitle=Orphanet+journal+of+rare+diseases&rft.au=Shmara%2C+Alyaa&rft.au=Lee%2C+Grace&rft.au=Mgdsyan%2C+Mania&rft.au=Hall%2C+Kathy&rft.date=2025-04-30&rft.eissn=1750-1172&rft.volume=20&rft.issue=1&rft.spage=206&rft_id=info:doi/10.1186%2Fs13023-025-03601-x&rft_id=info%3Apmid%2F40301993&rft.externalDocID=40301993 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1172&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1172&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1172&client=summon |